Treatment Strategies for Advanced Classical Hodgkin Lymphoma in the Times of Dacarbazine Shortage.

Abstract	The shortage of dacarbazine (DTIC) has created an acute and unprecedented crisis in the management of patients with classical Hodgkin lymphoma, with DTIC being an essential component of doxorubicin, bleomycin, vinblastine, and DTIC (ABVD) and prior attempts at omitting DTIC from ABVD leading to substantial loss of efficacy. In this review, we discuss the strategies to manage classical Hodgkin lymphoma during the DTIC shortage and propose a treatment algorithm on the basis of fitness and ability to receive anthracyclines safely.
Authors	Pallawi Torka, Eugene Przespolewski, Andrew M Evens
Journal	JCO oncology practice (JCO Oncol Pract) Vol. 18 Issue 7 Pg. 491-497 (07 2022) ISSN: 2688-1535 [Electronic] United States
PMID	35254922 (Publication Type: Journal Article, Review)
Chemical References	Bleomycin Vinblastine Dacarbazine Doxorubicin
Topics	Antineoplastic Combined Chemotherapy Protocols (pharmacology, therapeutic use) Bleomycin (therapeutic use) Dacarbazine (pharmacology, therapeutic use) Doxorubicin (pharmacology, therapeutic use) Hodgkin Disease (drug therapy, pathology) Humans Vinblastine (pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!